nodes	percent_of_prediction	percent_of_DWPC	metapath
Methsuximide—CYP2C19—Arformoterol—chronic obstructive pulmonary disease	0.255	0.413	CbGbCtD
Methsuximide—CYP2C19—Formoterol—chronic obstructive pulmonary disease	0.255	0.413	CbGbCtD
Methsuximide—CYP2C19—Prednisone—chronic obstructive pulmonary disease	0.107	0.174	CbGbCtD
Methsuximide—CACNA1G—Nicotine Activity on Chromaffin Cells—CHRNA3—chronic obstructive pulmonary disease	0.0336	0.435	CbGpPWpGaD
Methsuximide—Suicidal behaviour—Montelukast—chronic obstructive pulmonary disease	0.0192	0.0655	CcSEcCtD
Methsuximide—Gastrointestinal symptom NOS—Salbutamol—chronic obstructive pulmonary disease	0.00796	0.0271	CcSEcCtD
Methsuximide—Weight decreased—Roflumilast—chronic obstructive pulmonary disease	0.00554	0.0189	CcSEcCtD
Methsuximide—Aggression—Montelukast—chronic obstructive pulmonary disease	0.00553	0.0188	CcSEcCtD
Methsuximide—Aggression—Salbutamol—chronic obstructive pulmonary disease	0.00533	0.0182	CcSEcCtD
Methsuximide—Irritability—Aminophylline—chronic obstructive pulmonary disease	0.00451	0.0154	CcSEcCtD
Methsuximide—Tension—Roflumilast—chronic obstructive pulmonary disease	0.00419	0.0143	CcSEcCtD
Methsuximide—Nervousness—Roflumilast—chronic obstructive pulmonary disease	0.00415	0.0141	CcSEcCtD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—RAPGEF3—chronic obstructive pulmonary disease	0.00403	0.0522	CbGpPWpGaD
Methsuximide—Haematuria—Aminophylline—chronic obstructive pulmonary disease	0.00347	0.0118	CcSEcCtD
Methsuximide—Irritability—Montelukast—chronic obstructive pulmonary disease	0.00336	0.0115	CcSEcCtD
Methsuximide—Aminophenazone—CYP1A2—chronic obstructive pulmonary disease	0.00332	0.254	CrCbGaD
Methsuximide—Irritability—Salbutamol—chronic obstructive pulmonary disease	0.00324	0.0111	CcSEcCtD
Methsuximide—Ataxia—Salbutamol—chronic obstructive pulmonary disease	0.0032	0.0109	CcSEcCtD
Methsuximide—Insomnia—Roflumilast—chronic obstructive pulmonary disease	0.00315	0.0107	CcSEcCtD
Methsuximide—Decreased appetite—Roflumilast—chronic obstructive pulmonary disease	0.00303	0.0103	CcSEcCtD
Methsuximide—Eosinophilia—Montelukast—chronic obstructive pulmonary disease	0.00302	0.0103	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.00301	0.0103	CcSEcCtD
Methsuximide—Constipation—Roflumilast—chronic obstructive pulmonary disease	0.00298	0.0102	CcSEcCtD
Methsuximide—Feeling abnormal—Roflumilast—chronic obstructive pulmonary disease	0.00287	0.00979	CcSEcCtD
Methsuximide—Gastrointestinal pain—Roflumilast—chronic obstructive pulmonary disease	0.00285	0.00971	CcSEcCtD
Methsuximide—Tension—Aminophylline—chronic obstructive pulmonary disease	0.00279	0.00952	CcSEcCtD
Methsuximide—Urticaria—Roflumilast—chronic obstructive pulmonary disease	0.00277	0.00944	CcSEcCtD
Methsuximide—Nervousness—Aminophylline—chronic obstructive pulmonary disease	0.00277	0.00943	CcSEcCtD
Methsuximide—Abdominal pain—Roflumilast—chronic obstructive pulmonary disease	0.00276	0.00939	CcSEcCtD
Methsuximide—Drowsiness—Montelukast—chronic obstructive pulmonary disease	0.00272	0.00926	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Montelukast—chronic obstructive pulmonary disease	0.00269	0.00918	CcSEcCtD
Methsuximide—Hiccups—Prednisolone—chronic obstructive pulmonary disease	0.00269	0.00915	CcSEcCtD
Methsuximide—Haematuria—Arformoterol—chronic obstructive pulmonary disease	0.00264	0.00901	CcSEcCtD
Methsuximide—Haematuria—Formoterol—chronic obstructive pulmonary disease	0.00264	0.00901	CcSEcCtD
Methsuximide—Drowsiness—Salbutamol—chronic obstructive pulmonary disease	0.00262	0.00893	CcSEcCtD
Methsuximide—CYP2C19—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A2—chronic obstructive pulmonary disease	0.0026	0.0337	CbGpPWpGaD
Methsuximide—Vision blurred—Tiotropium—chronic obstructive pulmonary disease	0.00253	0.00863	CcSEcCtD
Methsuximide—Haematuria—Salbutamol—chronic obstructive pulmonary disease	0.0025	0.00851	CcSEcCtD
Methsuximide—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.00238	0.00813	CcSEcCtD
Methsuximide—CYP2C19—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A2—chronic obstructive pulmonary disease	0.00237	0.0307	CbGpPWpGaD
Methsuximide—Erythema multiforme—Montelukast—chronic obstructive pulmonary disease	0.00231	0.00786	CcSEcCtD
Methsuximide—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.0023	0.00786	CcSEcCtD
Methsuximide—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.00222	0.00755	CcSEcCtD
Methsuximide—Anorexia—Aminophylline—chronic obstructive pulmonary disease	0.00222	0.00755	CcSEcCtD
Methsuximide—Rash—Roflumilast—chronic obstructive pulmonary disease	0.0022	0.00749	CcSEcCtD
Methsuximide—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.0022	0.00748	CcSEcCtD
Methsuximide—Headache—Roflumilast—chronic obstructive pulmonary disease	0.00218	0.00744	CcSEcCtD
Methsuximide—Tension—Formoterol—chronic obstructive pulmonary disease	0.00213	0.00725	CcSEcCtD
Methsuximide—Tension—Arformoterol—chronic obstructive pulmonary disease	0.00213	0.00725	CcSEcCtD
Methsuximide—Nervousness—Arformoterol—chronic obstructive pulmonary disease	0.00211	0.00717	CcSEcCtD
Methsuximide—Nervousness—Formoterol—chronic obstructive pulmonary disease	0.00211	0.00717	CcSEcCtD
Methsuximide—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.0021	0.00716	CcSEcCtD
Methsuximide—Antipyrine—CYP1A2—chronic obstructive pulmonary disease	0.00209	0.16	CrCbGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—HDAC2—chronic obstructive pulmonary disease	0.00208	0.0269	CbGpPWpGaD
Methsuximide—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.00207	0.00706	CcSEcCtD
Methsuximide—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.00202	0.00689	CcSEcCtD
Methsuximide—Tension—Salbutamol—chronic obstructive pulmonary disease	0.00201	0.00684	CcSEcCtD
Methsuximide—Nervousness—Salbutamol—chronic obstructive pulmonary disease	0.00199	0.00677	CcSEcCtD
Methsuximide—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.00198	0.00676	CcSEcCtD
Methsuximide—Hiccups—Prednisone—chronic obstructive pulmonary disease	0.00195	0.00665	CcSEcCtD
Methsuximide—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.0019	0.00648	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.00189	0.00645	CcSEcCtD
Methsuximide—CYP2C19—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—chronic obstructive pulmonary disease	0.00189	0.0245	CbGpPWpGaD
Methsuximide—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.00187	0.00639	CcSEcCtD
Methsuximide—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.00185	0.00629	CcSEcCtD
Methsuximide—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.00184	0.00626	CcSEcCtD
Methsuximide—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.00179	0.00611	CcSEcCtD
Methsuximide—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.00174	0.00593	CcSEcCtD
Methsuximide—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.00173	0.00591	CcSEcCtD
Methsuximide—CYP2C19—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—chronic obstructive pulmonary disease	0.00172	0.0223	CbGpPWpGaD
Methsuximide—Primidone—CYP1A2—chronic obstructive pulmonary disease	0.00162	0.123	CrCbGaD
Methsuximide—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.0016	0.00545	CcSEcCtD
Methsuximide—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.0016	0.00545	CcSEcCtD
Methsuximide—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.00159	0.00543	CcSEcCtD
Methsuximide—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.00159	0.00542	CcSEcCtD
Methsuximide—Pethidine—SLC6A4—chronic obstructive pulmonary disease	0.00159	0.121	CrCbGaD
Methsuximide—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.00157	0.00536	CcSEcCtD
Methsuximide—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.00157	0.00536	CcSEcCtD
Methsuximide—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.00157	0.00534	CcSEcCtD
Methsuximide—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.00154	0.00525	CcSEcCtD
Methsuximide—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.00154	0.00524	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00153	0.0052	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00153	0.0052	CcSEcCtD
Methsuximide—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.00151	0.00516	CcSEcCtD
Methsuximide—Constipation—Formoterol—chronic obstructive pulmonary disease	0.00151	0.00516	CcSEcCtD
Methsuximide—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.00151	0.00515	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.0015	0.0051	CcSEcCtD
Methsuximide—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.00148	0.00506	CcSEcCtD
Methsuximide—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.00148	0.00504	CcSEcCtD
Methsuximide—Rash—Aminophylline—chronic obstructive pulmonary disease	0.00147	0.00499	CcSEcCtD
Methsuximide—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.00146	0.00499	CcSEcCtD
Methsuximide—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.00146	0.00497	CcSEcCtD
Methsuximide—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.00146	0.00497	CcSEcCtD
Methsuximide—Headache—Aminophylline—chronic obstructive pulmonary disease	0.00146	0.00496	CcSEcCtD
Methsuximide—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.00145	0.00495	CcSEcCtD
Methsuximide—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.00145	0.00494	CcSEcCtD
Methsuximide—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.00145	0.00493	CcSEcCtD
Methsuximide—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.00145	0.00493	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00144	0.00491	CcSEcCtD
Methsuximide—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.00143	0.00487	CcSEcCtD
Methsuximide—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.00142	0.00483	CcSEcCtD
Methsuximide—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.00141	0.00479	CcSEcCtD
Methsuximide—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.00141	0.00479	CcSEcCtD
Methsuximide—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.0014	0.00477	CcSEcCtD
Methsuximide—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.0014	0.00477	CcSEcCtD
Methsuximide—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.00139	0.00475	CcSEcCtD
Methsuximide—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	0.00138	0.00471	CcSEcCtD
Methsuximide—Rash—Tiotropium—chronic obstructive pulmonary disease	0.00138	0.00471	CcSEcCtD
Methsuximide—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.00138	0.00471	CcSEcCtD
Methsuximide—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.00138	0.00471	CcSEcCtD
Methsuximide—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.00138	0.00469	CcSEcCtD
Methsuximide—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.00138	0.00469	CcSEcCtD
Methsuximide—Headache—Tiotropium—chronic obstructive pulmonary disease	0.00137	0.00468	CcSEcCtD
Methsuximide—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.00137	0.00467	CcSEcCtD
Methsuximide—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.00137	0.00466	CcSEcCtD
Methsuximide—Irritability—Prednisone—chronic obstructive pulmonary disease	0.00135	0.00461	CcSEcCtD
Methsuximide—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.00133	0.00452	CcSEcCtD
Methsuximide—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.00132	0.0045	CcSEcCtD
Methsuximide—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.0013	0.00444	CcSEcCtD
Methsuximide—CYP2C19—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.00125	0.0162	CbGpPWpGaD
Methsuximide—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.00121	0.00413	CcSEcCtD
Methsuximide—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.00121	0.00413	CcSEcCtD
Methsuximide—CYP2C19—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.0012	0.0156	CbGpPWpGaD
Methsuximide—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.00119	0.00404	CcSEcCtD
Methsuximide—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.00117	0.00399	CcSEcCtD
Methsuximide—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.00117	0.00399	CcSEcCtD
Methsuximide—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.00115	0.0039	CcSEcCtD
Methsuximide—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.00114	0.00389	CcSEcCtD
Methsuximide—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.00112	0.00383	CcSEcCtD
Methsuximide—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.00112	0.00383	CcSEcCtD
Methsuximide—Rash—Formoterol—chronic obstructive pulmonary disease	0.00112	0.0038	CcSEcCtD
Methsuximide—Rash—Arformoterol—chronic obstructive pulmonary disease	0.00112	0.0038	CcSEcCtD
Methsuximide—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.00111	0.0038	CcSEcCtD
Methsuximide—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.00111	0.0038	CcSEcCtD
Methsuximide—Headache—Formoterol—chronic obstructive pulmonary disease	0.00111	0.00378	CcSEcCtD
Methsuximide—Headache—Arformoterol—chronic obstructive pulmonary disease	0.00111	0.00378	CcSEcCtD
Methsuximide—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.00111	0.00377	CcSEcCtD
Methsuximide—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.00111	0.00377	CcSEcCtD
Methsuximide—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.0011	0.00376	CcSEcCtD
Methsuximide—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.0011	0.00375	CcSEcCtD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—TLR4—chronic obstructive pulmonary disease	0.0011	0.0142	CbGpPWpGaD
Methsuximide—Rash—Montelukast—chronic obstructive pulmonary disease	0.00109	0.00372	CcSEcCtD
Methsuximide—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.00109	0.00372	CcSEcCtD
Methsuximide—Headache—Montelukast—chronic obstructive pulmonary disease	0.00109	0.0037	CcSEcCtD
Methsuximide—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.00106	0.00362	CcSEcCtD
Methsuximide—Phenobarbital—CYP1A1—chronic obstructive pulmonary disease	0.00106	0.0808	CrCbGaD
Methsuximide—Rash—Salbutamol—chronic obstructive pulmonary disease	0.00105	0.00359	CcSEcCtD
Methsuximide—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.00105	0.00359	CcSEcCtD
Methsuximide—Nausea—Formoterol—chronic obstructive pulmonary disease	0.00105	0.00358	CcSEcCtD
Methsuximide—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.00105	0.00358	CcSEcCtD
Methsuximide—Headache—Salbutamol—chronic obstructive pulmonary disease	0.00105	0.00357	CcSEcCtD
Methsuximide—Nausea—Montelukast—chronic obstructive pulmonary disease	0.00103	0.00351	CcSEcCtD
Methsuximide—Phenobarbital—CYP1A2—chronic obstructive pulmonary disease	0.00102	0.0779	CrCbGaD
Methsuximide—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000992	0.00338	CcSEcCtD
Methsuximide—Ketazolam—ALB—chronic obstructive pulmonary disease	0.000955	0.0729	CrCbGaD
Methsuximide—CYP2C19—Melatonin metabolism and effects—CYP1A2—chronic obstructive pulmonary disease	0.000928	0.012	CbGpPWpGaD
Methsuximide—CYP2C19—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000908	0.0118	CbGpPWpGaD
Methsuximide—CYP2C19—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000873	0.0113	CbGpPWpGaD
Methsuximide—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000866	0.00295	CcSEcCtD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—chronic obstructive pulmonary disease	0.000861	0.0112	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—NOS3—chronic obstructive pulmonary disease	0.000841	0.0109	CbGpPWpGaD
Methsuximide—Pethidine—ALB—chronic obstructive pulmonary disease	0.000835	0.0637	CrCbGaD
Methsuximide—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000804	0.00274	CcSEcCtD
Methsuximide—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000789	0.00269	CcSEcCtD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—chronic obstructive pulmonary disease	0.000779	0.0101	CbGpPWpGaD
Methsuximide—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000761	0.00259	CcSEcCtD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—IL6—chronic obstructive pulmonary disease	0.000747	0.00968	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—CXCL8—chronic obstructive pulmonary disease	0.000746	0.00966	CbGpPWpGaD
Methsuximide—CYP2C19—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.00072	0.00932	CbGpPWpGaD
Methsuximide—CYP2C19—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000675	0.00874	CbGpPWpGaD
Methsuximide—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000664	0.00226	CcSEcCtD
Methsuximide—CACNA1I—Developmental Biology—ADIPOQ—chronic obstructive pulmonary disease	0.00066	0.00854	CbGpPWpGaD
Methsuximide—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000633	0.00216	CcSEcCtD
Methsuximide—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.00063	0.00215	CcSEcCtD
Methsuximide—Phenytoin—ALB—chronic obstructive pulmonary disease	0.000615	0.0469	CrCbGaD
Methsuximide—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000605	0.00206	CcSEcCtD
Methsuximide—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000604	0.00206	CcSEcCtD
Methsuximide—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000603	0.00206	CcSEcCtD
Methsuximide—CYP2C19—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.0006	0.00778	CbGpPWpGaD
Methsuximide—Headache—Prednisolone—chronic obstructive pulmonary disease	0.0006	0.00205	CcSEcCtD
Methsuximide—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000595	0.00203	CcSEcCtD
Methsuximide—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000574	0.00196	CcSEcCtD
Methsuximide—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000569	0.00194	CcSEcCtD
Methsuximide—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000569	0.00194	CcSEcCtD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—TGFB1—chronic obstructive pulmonary disease	0.000556	0.0072	CbGpPWpGaD
Methsuximide—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000553	0.00188	CcSEcCtD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—IL6—chronic obstructive pulmonary disease	0.000551	0.00713	CbGpPWpGaD
Methsuximide—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.00055	0.00188	CcSEcCtD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—IL6—chronic obstructive pulmonary disease	0.000534	0.00691	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000531	0.00687	CbGpPWpGaD
Methsuximide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000519	0.00672	CbGpPWpGaD
Methsuximide—CYP2C19—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000512	0.00663	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—ADIPOQ—chronic obstructive pulmonary disease	0.000486	0.0063	CbGpPWpGaD
Methsuximide—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000476	0.00162	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—ADIPOQ—chronic obstructive pulmonary disease	0.000471	0.0061	CbGpPWpGaD
Methsuximide—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.00046	0.00157	CcSEcCtD
Methsuximide—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000443	0.00151	CcSEcCtD
Methsuximide—Rash—Prednisone—chronic obstructive pulmonary disease	0.000439	0.0015	CcSEcCtD
Methsuximide—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000439	0.00149	CcSEcCtD
Methsuximide—CYP2C19—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000436	0.00565	CbGpPWpGaD
Methsuximide—Headache—Prednisone—chronic obstructive pulmonary disease	0.000436	0.00149	CcSEcCtD
Methsuximide—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000421	0.00545	CbGpPWpGaD
Methsuximide—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000413	0.00141	CcSEcCtD
Methsuximide—CACNA1I—Developmental Biology—LEP—chronic obstructive pulmonary disease	0.00041	0.00531	CbGpPWpGaD
Methsuximide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000377	0.00488	CbGpPWpGaD
Methsuximide—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000372	0.00482	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—MMP9—chronic obstructive pulmonary disease	0.000345	0.00447	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—VEGFA—chronic obstructive pulmonary disease	0.00031	0.00401	CbGpPWpGaD
Methsuximide—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000306	0.00396	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—LEP—chronic obstructive pulmonary disease	0.000302	0.00391	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—LEP—chronic obstructive pulmonary disease	0.000293	0.00379	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—EGFR—chronic obstructive pulmonary disease	0.000279	0.00361	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000269	0.00348	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000266	0.00344	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—MMP9—chronic obstructive pulmonary disease	0.000254	0.00329	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—MMP9—chronic obstructive pulmonary disease	0.000246	0.00319	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MMP9—chronic obstructive pulmonary disease	0.000246	0.00319	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—VEGFA—chronic obstructive pulmonary disease	0.000228	0.00296	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000223	0.00289	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—VEGFA—chronic obstructive pulmonary disease	0.000221	0.00287	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—VEGFA—chronic obstructive pulmonary disease	0.000221	0.00286	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.00022	0.00285	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—IL6—chronic obstructive pulmonary disease	0.000214	0.00278	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—EGFR—chronic obstructive pulmonary disease	0.000206	0.00266	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—TGFB1—chronic obstructive pulmonary disease	0.000203	0.00263	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—EGFR—chronic obstructive pulmonary disease	0.000199	0.00258	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—EGFR—chronic obstructive pulmonary disease	0.000199	0.00258	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—TNF—chronic obstructive pulmonary disease	0.00019	0.00245	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	0.000189	0.00245	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000186	0.00241	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000184	0.00238	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MMP9—chronic obstructive pulmonary disease	0.000182	0.00235	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MMP9—chronic obstructive pulmonary disease	0.000176	0.00228	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000171	0.00222	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.000169	0.00219	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—VEGFA—chronic obstructive pulmonary disease	0.000163	0.00211	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000162	0.0021	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	0.00016	0.00207	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—IL6—chronic obstructive pulmonary disease	0.000158	0.00205	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—VEGFA—chronic obstructive pulmonary disease	0.000158	0.00204	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—IL6—chronic obstructive pulmonary disease	0.000153	0.00198	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—IL6—chronic obstructive pulmonary disease	0.000153	0.00198	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—TGFB1—chronic obstructive pulmonary disease	0.00015	0.00194	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—EGFR—chronic obstructive pulmonary disease	0.000147	0.0019	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—TGFB1—chronic obstructive pulmonary disease	0.000145	0.00188	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—EGFR—chronic obstructive pulmonary disease	0.000142	0.00184	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—TNF—chronic obstructive pulmonary disease	0.00014	0.00181	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—TNF—chronic obstructive pulmonary disease	0.000135	0.00175	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—APIP—chronic obstructive pulmonary disease	0.000131	0.00169	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—IL6—chronic obstructive pulmonary disease	0.000113	0.00146	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—IL6—chronic obstructive pulmonary disease	0.000109	0.00141	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	9.31e-05	0.00121	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	8.65e-05	0.00112	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	8.58e-05	0.00111	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GC—chronic obstructive pulmonary disease	8.42e-05	0.00109	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	7.83e-05	0.00101	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	6.24e-05	0.000808	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.6e-05	0.000596	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GCLC—chronic obstructive pulmonary disease	4.55e-05	0.000589	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	4.24e-05	0.000549	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CTGF—chronic obstructive pulmonary disease	4.15e-05	0.000537	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CYP1A2—chronic obstructive pulmonary disease	3.82e-05	0.000495	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.19e-05	0.000413	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.14e-05	0.000407	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.93e-05	0.000379	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.78e-05	0.00036	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ALB—chronic obstructive pulmonary disease	1.89e-05	0.000244	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—NOS3—chronic obstructive pulmonary disease	1.81e-05	0.000234	CbGpPWpGaD
